What a New Bladder Medicine Study Means for Dementia Risk

An older woman and her daughter review a medication list with a clinician at a consultation table.

Date

A medication review can bring the person’s symptoms, treatment goals and current prescriptions into one conversation. AI-generated conceptual illustration; the people shown are fictional, not study participants.

A new study of bladder medicines and dementia risk found no lower risk of newly recorded dementia with beta-3 agonists than with anticholinergic medicines after accounting for measured patient differences. It does not establish that either group is safer. Read the November 6 study in JAMA Network Open.

For caregivers, the useful next step is a medication conversation, not a prescription change based on a headline. The Alzheimer's Association advises families to discuss medication changes with the prescriber and report troubling side effects. See its medication safety guidance.

What the study examined

Researchers reviewed records for 830,393 adults starting overactive bladder medication, including anticholinergics such as oxybutynin and beta-3 medicines such as mirabegron.

The study was observational, not randomized, and excluded people with existing dementia. Researchers identified dementia through diagnosis codes or dementia-specific prescriptions. Median follow-up varied by group from about three to four years. See the study's methods and results.

Why the result needs care

Doctors may favor beta-3 medicines for people already at greater cognitive risk. This prescribing pattern, rather than the drug, could affect the comparison. The researchers acknowledge that unmeasured patient differences could explain their findings. Read the study discussion.

An accompanying editorial emphasizes that the result conflicts with some earlier research. It calls for stronger prospective evidence and says alternatives to strongly anticholinergic medicines, including beta-3 agonists, remain reasonable choices. Read the independent editorial.

For caregivers, the distinction matters: this study does not establish medication safety for someone who already has dementia.

Keep the individual person in the decision

The 2024 American Urological Association and SUFU guideline advises clinicians to discuss potential dementia and cognitive risks when prescribing antimuscarinic medicines, a type of anticholinergic. It also recommends reviewing how well treatment works and checking side effects after starting it. This new paper is not a replacement guideline. Read the professional guideline.

The right discussion includes the person's comfort and goals. Is urgency interrupting sleep? Are bathroom trips becoming difficult? Has treatment made daily life easier? Those observations give the prescriber something concrete to work with.

Questions to take to a medication review

Bring this informationAsk the care team
Current prescriptions, nonprescription products, supplements and dosesCould any medicines interact or contribute to the problems we are noticing?
When the bladder medicine started and what changed afterwardWhat benefit should we expect, and which side effects should prompt a call?
A short record of urgency, accidents and bathroom tripsDoes the pattern suggest overactive bladder or another cause, and what non-drug support could help?

The medication questions build on the Alzheimer's Association's safety advice. The bladder diary question reflects the AUA/SUFU guideline. These are conversation prompts, not instructions to stop or switch a drug.

Bladder care is about more than a prescription

New accidents deserve an assessment rather than an assumption that dementia is progressing. The Alzheimer's Association lists several possible contributors, including constipation, infection, medication effects and difficulty reaching or recognizing the bathroom. It recommends preserving privacy and making the bathroom easier to find and reach. Read its incontinence guidance.

Our guide to managing incontinence with dignity offers practical support for daily care. If several people share care, use the one-page dementia care handoff to point everyone to the current care plan and medication instructions.

The new research leaves an important question open. Families can still take a useful step today: bring their observations and a complete medication list to a clinician or pharmacist, and make decisions around the person being cared for.

This article is for general education and does not replace individualized medical advice.

Picture of Marcelo Oleas

Marcelo Oleas

Marcelo is the founder of DementiaHelp.io and a dedicated advocate for dementia caregivers. After spending over six years as a caregiver helping three family members navigating Frontotemporal Dementia, Lewy Body, and Alzheimer’s, he created this platform to share the practical resources and emotional support he found lacking during his own journey. Marcelo is also the President of M4 Worldwide, Inc., and a life coach specializing in helping others to nurture self-love in their personal growth journey.

** Ad Disclaimer: As an Amazon Associate, we earn from qualifying purchases. **

More
articles